The global Molybdenum-99 (Mo-99) market is set to reach $8.33 billion by 2035, growing at a compound annual growth rate of 4.89%. Starting from an estimated value of $5.4 billion in 2026, the trajectory is steady and underpinned by structurally rising demand. The figures come from a Healthcare Foresights analysis published on July 24, 2026.
Mo-99 is the parent isotope of Technetium-99m (Tc-99m), the most widely used radioisotope in diagnostic imaging worldwide. Tc-99m is employed in more than 80% of all nuclear medicine procedures globally — including SPECT scans for cardiac assessment, tumor detection, and bone function analysis. In the United States alone, it supports approximately 56,000 patient studies every day, according to April 2026 data. A defining characteristic of Mo-99 is that it cannot be stockpiled: with a half-life of just 66 hours, it requires continuous production and a precise, uninterrupted distribution chain. Any disruption in the supply chain translates directly into patient impact.
Production takes place primarily in nuclear research reactors, where uranium targets are irradiated with neutrons to generate Mo-99 as a fission product. The process is well established, but reliance on a limited number of facilities — concentrated in North America and Europe — has historically created supply chain vulnerabilities. North America currently holds approximately 42% of the global market share, followed by Europe at 29% and Asia-Pacific at 21%. The latter region is expanding rapidly, with nuclear medicine investment up 50% in recent years. Key market players include Curium Pharma, Eckert & Ziegler, and Rosatom. In February 2024, Curium Pharma announced the expansion of its Mo-99 production and distribution network to stabilize the global supply of Tc-99m generators.
The most significant trend reshaping the sector is the diversification of production methods. Cyclotrons and linear accelerators now make it possible to produce Mo-99 and Tc-99m without nuclear reactors, enabling a localized and decentralized approach. This reduces dependence on a handful of large facilities and makes the supply chain more resilient. Accelerator-based methods are considered especially suited for on-site production directly at or near hospital centers, eliminating many of the logistical challenges posed by Tc-99m’s short half-life of approximately six hours. Market projections suggest that non-reactor-based production could grow by 45% over the next decade. South Korea, for instance, is actively investing in domestic Mo-99 production capacity with the goal of reducing imports and strengthening supply security.
The implications of this growth extend beyond medicine. An expanding Mo-99 market reaffirms the central role of nuclear technology — both in the traditional form of research reactors and through emerging accelerator-based solutions — as a pillar of global healthcare infrastructure. Countries investing today in domestic production capacity are positioning themselves for self-sufficiency in a sector where foreign dependence has direct consequences for public health. The SPECT imaging segment alone is forecast to grow at a CAGR of 4.9% through 2035. As the global population ages and oncological and cardiovascular diagnoses increase, demand for Mo-99 will not slow. Those who build robust, diversified supply chains today will hold a competitive advantage in 2035 that will be difficult to overcome.
